More than a dozen drugmakers are competing to develop hard-to-abuse pain treatments following a key ruling from the FDA. "Over time, it should be a scientific race across the whole pharmaceutical industry to create a market where all opioids have abuse-deterrent properties," said Gary L. Stiles, Purdue Pharma's senior vice president of research and development. The competition could make the cost of pain drugs go up and further boost an already profitable market.

Related Summaries